Business description: StemRIM

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

Executive Committee: StemRIM

Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 2022-09-30
Chief Executive Officer 58 2023-10-24
Chief Administrative Officer - -
President 56 2010-03-31

Composition of the Board of Directors: StemRIM

Director TitleAgeSince
Director/Board Member 66 2007-01-31
Director/Board Member 58 2019-02-28
Director/Board Member 54 2019-09-30
Director/Board Member 50 2020-10-13

Shareholders: StemRIM

NameStocks%Valuation
15.92 %
9,980,000 15.92 % 19 M ¥
8.615 %
5,400,000 8.615 % 10 M ¥
7.418 %
4,650,000 7.418 % 9 M ¥
7.317 %
4,586,300 7.317 % 9 M ¥
5.392 %
3,380,000 5.392 % 6 M ¥

Holdings: StemRIM

NameStocks%Valuation
1000% 187 $

Company details: StemRIM

StemRIM, Inc.

Saito Bio Incubator, 3/F

567-0085, Osaka

+

http://stemrim.com
address StemRIM(4599)

Biopharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
-2.25%+14.85%+9.09%-60.81% 140M
+1.00%+4.39%+43.53%-0.12% 80.48B
+0.97%+3.30%-2.19%+26.99% 51.06B
-0.73%-2.51%+11.94%+164.79% 48.19B
-0.74%+3.26%-49.46%-48.10% 46.5B
+0.85%+2.12%+55.82%-23.03% 31.12B
-0.03%+18.18%+136.71%-37.28% 25.41B
-0.21%+1.81%+40.38%+82.80% 24.43B
-1.42%-1.11%-2.29%+189.51% 21.11B
-1.47%-1.99%+63.31%+107.38% 16.28B
Average -0.21%+5.10%+30.68%+40.21% 34.47B
Weighted average by Cap. +0.22%+3.24%+25.67%+38.21%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise